

COVAX GLOBAL SUPPLY FORECAST

JANUARY 20, 2021

CEPI



The COVAX Global Supply Forecast aims to provide an up-to-date overview of the supply of safe and effective vaccines to the COVAX Facility. Our goal is to offer economies participating in COVAX as much clarity as possible on when we expect the doses we have secured to start arriving. To this end, we provide both a global overview as well as specific regional forecasts.

According to our forecasting and assuming funding availability, we expect as many as ~1.8 billion doses to be available to the 92 economies of the Gavi COVAX Advance Market Commitment (AMC) in 2021, corresponding to ~27% coverage of AMC populations.¹

Our forecasting indicates that we should fulfil the requests for vaccine placed by Self-Financing Participants in the second half of 2021.

There are many uncertainties affecting the supply of COVID-19 vaccines in 2021, not least around manufacturing capacity, regulation, funding availability, final contract terms and the readiness of countries themselves to begin their national COVID-19 vaccination programmes. We list these caveats in the right hand column of each slide.


In recognition of the fast-changing nature of COVAX's supply outlook, and of the need to balance uncertainty with predictability, COVAX is committed to regularly updating this forecast.

¹ India handled exceptionally as decided by the Gavi Board.

COVAX FACILITY CANDIDATE-SPECIFIC SUPPLY 2021 AND 2022

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Mn doses, 2021 and 2022¹




¹ The COVAX Facility has signed legal agreements with Serum Institute of India (SII), AstraZeneca, and Pfizer/BioNTech; a Memorandum of Understanding with Johnson & Johnson (J&J); and a Statement of Intent with Sanofi-GSK.

COVAX FACILITY GLOBAL SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.


Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

COVAX FACILITY GLOBAL SUPPLY FORECAST BY AMC-ELIGIBLE AND SFP

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹

■ AMC
■ SFP



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

COVAX FACILITY GLOBAL SUPPLY FORECAST BY REGION

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M).

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches ("batch release").

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant's share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

COVAX FACILITY GLOBAL SUPPLY FORECAST BY CANDIDATE

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M).

² "Other" candidates include all those currently under active negotiation.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches ("batch release").

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant's share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.


WHO REGION- SPECIFIC VIEW



AFRO SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

EMRO SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

EURO SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches ("batch release").

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant's share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

PAHO SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

SEARO SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.


Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

WPRO SUPPLY FORECAST 2021

PRELIMINARY AND SUBJECT TO ASSUMPTIONS
As per 2021-01-20

COVAX Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).


Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.


OTHER VIEWS OF THE DATA



AU SUPPLY FORECAST 2021

COVAX Available Supply, Cumulative, Mn doses, 2021¹

■ AMC
■ SFP



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

² Signed agreements include legally-binding agreements, memoranda of understanding, and statements of intent.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.



CEPI

